Physician profile
Mark L Mullens
NPI 1114904679
$3,081.83
in general payments reported to CMS, 2019-2025
26 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $191 · 2021: $335 · 2022: $811 · 2023: $634 · 2024: $818 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $410.53 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $304.67 | 2019-2025 | |
| Pfizer INC. | $291.71 | 2022-2025 | |
| Abbott Laboratories | $245.77 | 2022-2023 | Mitraclip, Gallant |
| Amgen INC. | $235.47 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $192.44 | 2022-2024 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.15 | 2022-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $152.71 | 2023-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $148.98 | 2020-2024 | Farxiga, Wainua |
| Abiomed | $145.75 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $132.42 | 2022-2024 | Camzyos |
| Silk Road Medical, INC. | $131.00 | 2022 | |
| Atricure, INC. | $128.74 | 2023 | |
| Esperion Therapeutics, INC. | $85.80 | 2023-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $70.21 | 2025 | Amvuttra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.01 | 2020-2023 | |
| Actelion Pharmaceuticals US, INC. | $46.57 | 2022 | |
| Amarin Pharma, INC. | $25.91 | 2019-2021 | |
| Acutus Medical, INC. | $21.87 | 2020 | |
| Braintree Laboratories, INC. | $16.40 | 2019 | |
| Medtronic Vascular, INC. | $14.18 | 2020 | |
| Irhythm Technologies, INC. | $13.77 | 2019 | |
| Scpharmaceuticals INC. | $13.22 | 2024 | |
| Chiesi USA, INC. | $12.38 | 2020 | |
| Boston Scientific Corporation | $11.48 | 2021 | |
| Lemaitre Vascular, INC. | $8.69 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mullens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.